About the Company
Tradipitant (VLY-686 or LY686017) is an experimental drug that is a neurokinin 1 antagonist. It works by blocking substance P, a small signaling molecule. Originally, this compound was owned by Eli Lilly and named LY686017. VLY-686 was purchased by Vanda Pharmaceuticals from Eli Lilly and Company in 2012. Vanda Pharmaceuticals is a U.S. pharmaceutical company that as of November 2015 only has three drugs in their product pipeline: tasimelteon, VLY-686, and iloperidone.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $VNDA News
Vanda (VNDA) Rejects Takeover Interest From Future Pak, Stock Up
Vanda Pharmaceuticals Inc. VNDA announced that its board of directors has unanimously rejected a potential acquisition bid by ...
Shareholder Capital Delivers Letter to Independent Members of the Board of Vanda Pharmaceuticals
“ShareCap”), a significant shareholder of Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) (“Vanda” or the “Company”) holding over 200,000 shares of the Company’s common stock, announced today that they have ...
Investors Heavily Search Vanda Pharmaceuticals Inc. (VNDA): Here is What You Need to Know
Vanda Pharmaceuticals (VNDA) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term ...
Why Vanda Pharmaceuticals Stock Is Skyrocketing Today
Shares of Vanda Pharmaceuticals ( VNDA 37.78%) were skyrocketing 37.8% higher as of 10:09 a.m. ET on Wednesday. The huge gain ...
Vanda Pharmaceuticals Reacts to U.S. Supreme Court's Denial of its Petition in HETLIOZ® ANDA Litigation
Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the Supreme Court denied Vanda's petition for a writ of certiorari in its HETLIOZ® Abbreviated New Drug Application litigation ...
Supreme Court Denies Vanda Pharma' Petition In HETLIOZ Litigation Against Teva, Apotex
The U.S. Supreme Court denied Vanda Pharmaceuticals Inc.'s (VNDA) petition for a writ of certiorari in its HETLIOZ Abbreviated New ...
D.C. biotech adopts poison pill after rejecting acquisition offer
A D.C. biotech has adopted a shareholder rights plan, better known as a poison pill, after rejecting an unsolicited ...
SCOTUS Scraps Vanda’s Bid for Guidance on Obviousness Standard
The U.S. Supreme Court today denied a petition for certiorari seeking clarification from the Court on the proper standard for ...
Vanda (VNDA) to Report Q1 Earnings: What's in the Cards?
On Vanda's (VNDA) first-quarter 2024 earnings call, investors' focus is likely to be on the sales performance of its marketed ...
Vanda Pharmaceuticals Inc VM4
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Loading the latest forecasts...